Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy

  • Authors:
    • Masahiko Sumitani
    • Toru Ogata
    • Akina Natori
    • Jun Hozumi
    • Nobutake Shimojo
    • Kumiko Kida
    • Hideko Yamauchi
    • Teruo Yamauchi
  • View Affiliations

  • Published online on: April 8, 2016     https://doi.org/10.3892/br.2016.648
  • Pages: 758-760
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The phosphorylated form of the high-mole­cular‑weight neurofilament heavy subunit (pNF-H) is a major structural protein in axons. The pNF-H level is elevated in the serum of certain patients with central nervous disorders, including chemotherapy‑induced cognitive impairment. The present study was conducted to elucidate the potential role of pNF‑H as a marker of chemotherapy‑induced peripheral neuropathy (CIPN). A total of 71 patients with early breast cancer in various stages of treatment (following 1, 3 or 7 cycles of chemotherapy, or a previous history of breast cancer chemotherapy) were assessed with a self-administered PainDETECT questionnaire [pain location, pain intensity on an 11‑point numeric rating scale (NRS), and various pain qualities] and a single serum pNF-H measurement. Patients were divided into two groups based on the presence or absence of bilateral symmetric pain in the distal portions of the extremities [CIPN(+) or CIPN(-)]. The χ2 and Mann-Whitney tests were used for statistical analyses. Among the participants, only 8 patients complained of CIPN. Their pain intensity was 3.5±1.9 (mean ± standard deviation) compared with 1.5±1.8 in the CIPN(-) group (P<0.01). The NRS of numbness in the CIPN(+) group was significantly higher (2.4±1.4) than that of the CIPN(-) group (1.0±1.0). Increased pNF‑H levels were observed in 37.5% of the CIPN(+) patients and in 23.8% of CIPN(-) patients (P=0.40). In conclusion, CIPN is observed in the most distal portions of the peripheral nerves that are composed of dendrites but not axons. Although serum pNF‑H is a biomarker of axonal damage, it is not useful as a marker of CIPN.
View References

Related Articles

Journal Cover

June-2016
Volume 4 Issue 6

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sumitani M, Ogata T, Natori A, Hozumi J, Shimojo N, Kida K, Yamauchi H and Yamauchi T: Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy. Biomed Rep 4: 758-760, 2016
APA
Sumitani, M., Ogata, T., Natori, A., Hozumi, J., Shimojo, N., Kida, K. ... Yamauchi, T. (2016). Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy. Biomedical Reports, 4, 758-760. https://doi.org/10.3892/br.2016.648
MLA
Sumitani, M., Ogata, T., Natori, A., Hozumi, J., Shimojo, N., Kida, K., Yamauchi, H., Yamauchi, T."Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy". Biomedical Reports 4.6 (2016): 758-760.
Chicago
Sumitani, M., Ogata, T., Natori, A., Hozumi, J., Shimojo, N., Kida, K., Yamauchi, H., Yamauchi, T."Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy". Biomedical Reports 4, no. 6 (2016): 758-760. https://doi.org/10.3892/br.2016.648